Literature DB >> 22947412

Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study.

Renata Linertová1, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Manuel Hens-Pérez, Panos Kanavos, Domenica Taruscio, Arrigo Schieppati, Rumen Stefanov, Márta Péntek, Claudia Delgado, Johann-Matthias Graf von der Schulenburg, Ulf Persson, Karine Chevreul, Giovanni Fattore, Melany Worbes-Cerezo, Mark Sefton, Julio López-Bastida.   

Abstract

OBJECTIVES: The BURQOL-RD project is intended to develop a disease based model capable of quantifying the socio-economic burden and health-related quality of life for patients with rare diseases (RDs) and their caregivers in Europe. We described the methodology used to select a set of 10 RDs to be approached in a pilot study.
METHODS: BURQOL-RD project includes 23 partners from 8 European countries: Spain, UK, France, Germany, Sweden, Italy, Hungary and Bulgaria. A two-round Delphi panels in combination with Carroll diagram was used to generate consensus in the selection of the 10 RDs among the project participants.
RESULTS: The two Delphi rounds yielded a prioritised list, to which the Carroll diagram was applied, taking into account three determinants: prevalence, availability of effective treatment and need for carer. The final set of RD to be studied was obtained: cystic fibrosis, Prader-Willi syndrome, haemophilia, duchenne muscular dystrophy, epidermolysis bullosa, fragile X syndrome, scleroderma, mucopolysaccharidosis, juvenile idiopathic arthritis and histiocytosis.
CONCLUSIONS: This methodology permitted the generation of an equilibrated set of RDs for the pilot study of BURQOL-RD project. The model will be suitable for application in a wide range of RDs.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22947412     DOI: 10.1016/j.healthpol.2012.08.001

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  16 in total

1.  Social/economic costs and health-related quality of life in patients with histiocytosis in Europe.

Authors:  Georgi Iskrov; Itziar Astigarraga; Rumen Stefanov; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Arrigo Schieppati; Domenica Taruscio; Márta Péntek; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-04

2.  Social/economic costs and health-related quality of life in patients with rare diseases in Europe.

Authors:  Julio López-Bastida; Juan Oliva-Moreno; Renata Linertová; Pedro Serrano-Aguilar
Journal:  Eur J Health Econ       Date:  2016-03-29

3.  Networking Across Borders for Individuals with Organic Acidurias and Urea Cycle Disorders: The E-IMD Consortium.

Authors:  Stefan Kölker; Dries Dobbelaere; Johannes Häberle; Peter Burgard; Florian Gleich; Marshall L Summar; Steven Hannigan; Samantha Parker; Anupam Chakrapani; Matthias R Baumgartner
Journal:  JIMD Rep       Date:  2015-02-22

Review 4.  Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?

Authors:  Devidas Menon; Tania Stafinski; Andrea Dunn; Hilary Short
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

5.  Health-Related Quality of Life and Perceived Burden of Informal Caregivers of Patients with Rare Diseases in Selected European Countries.

Authors:  Cristina Valcárcel-Nazco; Yolanda Ramallo-Fariña; Renata Linertová; Juan Manuel Ramos-Goñi; Lidia García-Pérez; Pedro Serrano-Aguilar
Journal:  Int J Environ Res Public Health       Date:  2022-07-05       Impact factor: 4.614

6.  Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe.

Authors:  Márta Péntek; László Gulácsi; Valentin Brodszky; Petra Baji; Imre Boncz; Gábor Pogány; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Georgi Iskrov; Arrigo Schieppati; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-09

7.  Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe.

Authors:  Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Manuel Posada-de-la-Paz; Pedro Serrano-Aguilar; Panos Kanavos; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; Petra Baji; Claudia Delgado; Johann Matthias Graf von der Schulenburg; Ulf Persson; Karine Chevreul; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-02

8.  Social/economic costs and health-related quality of life in patients with scleroderma in Europe.

Authors:  Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Panos Kanavos; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; Márta Péntek; Claudia Delgado; Johann Mathias von der Schulenburg; Ulf Persson; Karine Chevreul; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-02

9.  Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe.

Authors:  Aris Angelis; Panos Kanavos; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; Valentin Brodszky; Johann Matthias Graf von der Schulenburg; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-23

10.  Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.

Authors:  Aris Angelis; Panos Kanavos; Julio López-Bastida; Renata Linertová; Elena Nicod; Pedro Serrano-Aguilar
Journal:  BMC Health Serv Res       Date:  2015-09-28       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.